Catequentinib - Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical
Alternative Names: AL-3818; ALTN; Anlotinib; Anlotinib hydrochloride; Anrotinib; Catequentinib Hydrochloride; FOCUS V; QezzaqarLatest Information Update: 13 Nov 2026
At a glance
- Originator Advenchen Laboratories; Jiangsu Chia-Tai Tianqing Pharmaceutical
- Developer Advenchen Laboratories; Akeso Biopharma; Chia Tai Tianqing Pharmaceutical Group; Henan Cancer Hospital; Peking University People's Hospital
- Class Amines; Antineoplastics; Cyclopropanes; Ethers; Fluorinated hydrocarbons; Indoles; Quinolines; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
-
Orphan Drug Status
Yes - Ovarian cancer; Soft tissue sarcoma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Medullary thyroid cancer; Non-small cell lung cancer; Small cell lung cancer; Soft tissue sarcoma; Thyroid cancer
- Preregistration Endometrial cancer
- Phase III Alveolar soft part sarcoma; Colorectal cancer; Gastric cancer; Leiomyosarcoma; Liver cancer; Nasopharyngeal cancer; Synovial sarcoma
- Phase II Bone cancer; Cancer; Cervical cancer; Cholangiocarcinoma; Ewing's sarcoma; Fallopian tube cancer; Gastrointestinal cancer; Gastrointestinal stromal tumours; Glioblastoma; Head and neck cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Phase I/II Acral lentiginous melanoma
- No development reported Solid tumours
Most Recent Events
- 30 Oct 2026 Regulatory submission withdrawn for Leiomyosarcoma in European Union (PO)
- 30 Oct 2026 Regulatory submission withdrawn for Synovial sarcoma in European Union (PO)
- 18 Sep 2026 Advenchen Laboratories requests a re-examination of the negative opinions issued by a EMA for marketing authorisation application (MAA) for Catequentinib for treatment of Synovial sarcoma and Leiomysarcoma